URINARY TRACT INFECTIONS--IMMUNE BASIS OF SUSCEPTIBILITY
Project Number5R01DK044378-06
Contact PI/Project LeaderHOPKINS, WALTER J
Awardee OrganizationUNIVERSITY OF WISCONSIN-MADISON
Description
Abstract Text
DESCRIPTION: (Adapted from the applicant's abstract) UTI remain a
common and serious clinical problem that affect 10-15 percent of all
women in their lifetime. Women seeking treatment for acute UTI account
for over 5 million visits to physician's offices annually in the United
States. Health care costs to treat only uncomplicated lower tract
infections are nearly one billion dollars per year. The most accepted
hypothesis for the pathophysiology of ascending UTI in susceptible women
is that uropathogens carried in the fecal flora sequentially colonize
the vaginal introitus, urethra, bladder, and finally the kidneys. E.
coli strains are responsible for the majority of UTIs and have specific
virulence factors such as adhesins for uroepithelial cell receptors,
certain O and K antigens, and hemolysins. The reasons for increased
susceptibility of female children and certain adult women are unknown
but may be due to increased binding of E. coli to epithelial cells
lining the vagina and bladder in conjunction with decreased levels of
urinary antibody to infecting organisms. The roles of immune defects in
UTI have not been comprehensively studied, although immunologic
hyporesponsiveness in UTI may be a critical and heretofore undefined
factor in explaining susceptibilities. The author's work with animal
models of increased susceptibility to UTI has shown that: 1) severe T and
B cell deficiencies decrease the ability of mice to resolve an
infection; 2) induced hyporesponsiveness to E. coli in monkeys leads to
poor resolution of an E. coli UTI; 3) increased levels of serum and
urinary anti E. coli antibody correlate with early resolution of an E.
coli UTI; 4) inbred mouse strains have variable susceptibility to an E.
coli UTI; and 5) the specificities of anti E. coli antibodies produced
in mice correlate with susceptibility to UTI. Studies of patients with
recurrent UTI's have shown that they have different patterns of antibody
responses to E. coli antigens than nonsusceptible women and different
frequencies of some major histocompatibility antigens. The proposed
research will focus on defining an immunogenetic basis of susceptibility
to UTIs. It will: 1) define the nature and role of genetically
determined immunodeficiency in murine UTI susceptibility; 2) determine
the role of acquired immunologic hyporesponsiveness in development of
UTIs; and 3) investigate the heritability of susceptibility to UTIs.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
B lymphocyteEscherichia coliMHC class II antigenT cell receptorT lymphocyteadult human (21+)antibacterial antibodybacterial antigensbactericidal immunitychild (0-11)family geneticsfemalegenetic strainhuman subjectimmune tolerance /unresponsivenessimmunodeficiencyimmunogeneticsimmunopathologylaboratory mouserelapse /recurrenceurinary bladder epitheliumurinary tract infectionvirulencewestern blottings
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
161202122
UEI
LCLSJAGTNZQ7
Project Start Date
01-May-1992
Project End Date
30-June-1998
Budget Start Date
20-August-1997
Budget End Date
30-June-1998
Project Funding Information for 1997
Total Funding
$212,531
Direct Costs
$149,867
Indirect Costs
$62,664
Year
Funding IC
FY Total Cost by IC
1997
National Institute of Diabetes and Digestive and Kidney Diseases
$212,531
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DK044378-06
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DK044378-06
Patents
No Patents information available for 5R01DK044378-06
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DK044378-06
Clinical Studies
No Clinical Studies information available for 5R01DK044378-06
News and More
Related News Releases
No news release information available for 5R01DK044378-06
History
No Historical information available for 5R01DK044378-06
Similar Projects
No Similar Projects information available for 5R01DK044378-06